NOTTINGHAM, U.K.—Sygnature Discovery, a leading drug discovery and preclinical services company, has appointed Dr. Nick Moore as senior director of business development—a newly created role to promote the in-vivo pharmacology and consultancy services offered by RenaSci, a wholly owned subsidiary company.
Moore is an internationally recognized drug discovery and development specialist who has spent nearly 40 years working in the field of in-vivo pharmacology. Previous roles include research appointments at Eli Lilly and Co., Lundbeck Research USA and Albany Molecular Research Inc. (AMRI), as well as business development positions at Brains On-Line and Charles River Laboratories. He earned his Ph.D. in neuropharmacology from the University of Birmingham, and his career highlights include a key involvement in the development of Lilly’s antipsychotic drug Zyprexa (olanzapine).
One of Moore’s key tasks will be to ensure that the synergistic in-vitro and in-vivo services and drug discovery expertise offered by Sygnature Discovery and RenaSci are maximized for the benefit of clients.
“I plan to focus on growing the in-vivo pharmacology business and ensure that both current and new customers are aware of the expanded service offering that the wider Sygnature Group is now able to provide,” Moore commented.
“Nick is a very experienced drug discovery scientist who brings a huge amount of in-vivo pharmacology know-how and proficiency into the business,” stated Dr. Paul Clewlow, Sygnature Discovery’s senior vice president of business development and a member of the board at Sygnature and RenaSci. “I am pleased that Nick has joined my team, as he will work closely with colleagues at RenaSci and Sygnature to convey the enhanced capabilities and expertise we offer to clients and identify new in-vivo pharmacology capabilities that will complement and augment our current integrated offering.”
RenaSci, founded in 2001, became part of the Sygnature Group in July 2018, following several successful project collaborations with joint clients. Sygnature and RenaSci were among the first companies to be established at BioCity Nottingham, the R&D site where Boots Pharmaceuticals discovered ibuprofen. The strategic acquisition of RenaSci by Sygnature stemmed from, as the parent company puts it, “a long-standing mutual respect between the organizations and the firm belief by Sygnature that combining the two companies would be beneficial not only to their customers, but ultimately to patients with considerable unmet medical need in abuse and dependence, CNS disorders, obesity, diabetes, NASH and kidney disease.”
“We realized that RenaSci and Sygnature Discovery were highly complementary businesses because we have a strong shared focus on high-quality science and delivering new and efficacious drugs to patients,” said Dr. Sharon Cheetham, executive director at RenaSci. “I am delighted to welcome Nick to the group, and we look forward to working with him to expand our business and better serve our clients in the drug discovery and preclinical sector.”